Nov 16, 2022 / 09:10AM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Good morning, everyone. Well, thank you for joining us on day 2 of the 2022 London Global Healthcare Conference here at Jefferies, I'm Michael Yee, Managing Director and Biotechnology Analyst. I'm really happy to have up here with me Stu Arbuckle, Executive Vice President and Chief Operating Officer of Vertex. Obviously, Vertex has a ton of stuff going on, both commercially and in the pipeline. I know, Stu, do you want to give a brief overview and some quick highlights, and then we'll go into some of the pressing topics of issue, and we'll have a good discussion.
Stuart A. Arbuckle - Vertex Pharmaceuticals Incorporated - Executive VP & COO
All right. Thank you, Mike. Thank you to you. Thanks to Jefferies for the invitation to be here. Great to see so many people in the room, and good morning, good afternoon to those on the webcast.
First thing I would like to draw your attention to our Safe Harbor statement. I'll obviously be making forward-looking statements. There are
Vertex Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers